CTLA4 and central nervous system cancer: When mAbs for CTLA-4 and PD-L1, together with the IDO inhibitor, 1-MT, were administered to mice bearing glioma, Treg levels in glioma microenvironment decreased significantly, and the combination was more effective than the single agent [138].